<DOC>
	<DOCNO>NCT02589925</DOCNO>
	<brief_summary>Phase 1 study evaluate safety combine bilateral subthalamic nucleus ( STN ) basal nucleus Meynert ( NBM ) stimulation treat levodopa responsive motor symptom Parkinsonism cognitive dysfunction patient advance Parkinson 's disease mild moderate dementia .</brief_summary>
	<brief_title>Combined Subthalamic Nucleus Basalis Meynert Deep Brain Stimulation Parkinson 's Disease With Dementia</brief_title>
	<detailed_description>Combined subthalamic Nucleus basalis Meynert Deep Brain Stimulation Parkinson 's disease dementia DEMPARK-DBS STUDY Indication : Parkinson 's disease mild moderate dementia Primary Objective : To provide proof safety combine bilateral subthalamic nucleus ( STN ) basal nucleus Meynert ( NBM ) stimulation treat levodopa responsive motor symptom Parkinsonism cognitive dysfunction patient advance Parkinson 's disease mild moderate dementia . Exploratory Objectives : To determine additional NBM stimulation improve slow progression cognitive decline patient advance Parkinson 's disease mild moderate dementia Test Device : Boston Scientific Corporation ( BSC ) Neuromodulation Vercise™ System . A neurostimulation device consist implantable pulse generator ( IPG ) , integrate rechargeable battery , two DBS lead , splitter allow control four electrode , surgical tool , external device ( program system , remote control , charge system ) . Device Description : The Vercise™ system IPG multiple independent current control pulse generator . The system identical form factor dimension commercially available 22-cc Precision Spinal Cord Stimulation II IPG . To allow delivery stimulation pulse four DBS electrode different stimulation frequency ( 100-200 Hz STN 20-80 Hz NBM ) splitter Precision Spinal Cord Stimulation system use . Study Design : Prospective single center Phase 1b study double-blind randomize delayed activation basal nucleus Meynert neurostimulation ( staggered onset design ) Planned Number Subjects : 12 patient Planned Number Sites / Countries : Single center Germany Primary Endpoint : Safety combine bilateral subthalamic nucleus ( STN ) basal nucleus Meynert ( NBM ) stimulation determine spontaneously report adverse event . Exploratory Endpoints : - Change global cognitive function measure ADAS-cog - Change global clinical impression measure ADAS-CGIC - Change activity daily life measure ADCS-ADL UPDRS II - Change neuropsychiatric symptom measure BDI Neuropsychiatric Inventory ( NPI ) - Change frontal executive function measure follow test : D-KEFS verbal fluency battery , Wisconsin Card Sorting Test ( modify version ) , Trail Making Task Part A + B , Stroop Test ( Victoria Version ) , Symbol Digit Modalities Test - Change performance Brief Test Attention ( BTA ) - Change apathy measure Starkstein Apathy Scale - Change motor function assess UPDRS III - Change quality life assess PDQ39 EQ-5d - Change caregiver burden/quality life measure SF-36 Health Economics Endpoints : - Gain quality adjust life-years ( QUALY ) Method Assigning Patients Treatment : Eligible patient consent participation meet inclusion none exclusion criterion receive follow setting pre-specified randomized order NBM neurostimulation visit 2 : - sham stimulation setting 0 V , 60 µs , 20 Hz - test stimulation setting 60µs , 20 Hz individually adjust amplitude ( could additionally verify GUIDE visualization tool ) threshold adverse effect Study Assessments : The following assessment conduct derive study endpoint : - ADAS-Cog - ADAS-CGIC - ADCS-ADL UPDRS II - BDI - NPI - Verbal Fluency D-KEFS battery , Wisconsin Card Sorting Test ( modify version ) , Trail Making Task Part A + B , Stroop Test ( Victoria Version ) , Symbol Digit Modalities Test - Brief Test Attention - Starkstein Apathy Scale - UPDRS III - Dyskinesia : Clinical Dyskinesia Rating Scale ( CDRS ) - PDQ39 EQ-5d - Caregiver burden assessment/SF36 - Direct indirect cost ( treatment , loss caregiver productivity , loss patient productivity , etc . ) Study Schedule : - Screening ( 0 4 week prior inclusion ) - Presurgical baseline evaluation ( motor state , cognitive test best motor state ) ( 0 4 week prior surgery ) - DBS Implant Procedure - Postsurgical baseline evaluation ( motor state , cognitive test best motor state ) 4±1 week surgery activation subthalamic neurostimulation use individualized stimulation parameter standard monopolar review - Visit 1 ( 12 week activation STN neurostimulation ) : motor off/on-medication + STN stimulation state , cognitive test motor + STN stimulation state - Randomization blind activation NBM neurostimulation accord 1:1 scheme - Visit 2 ( 24 week randomization ) : motor off-medication ± stimulation state , cognitive test motor + STN stimulation state ± NBM stimulation state - Activation NBM neurostimulation patient - Visit 3 ( 48 week activation NBM stimulation - e.g . 24 week Visit 2 NBM neurostimulation group vs. 48 week ) : motor -medication ± stimulation state , cognitive test motor + STN stimulation state + NBM stimulation state - Annual follow-up visit 5 year activation NBM stimulation Required Medication Therapy Patients must stable dos antiparkinsonian antidementia medication least 4 week prior screen assessment . Medications dosage may adjust necessary DBS implant surgery . Study Duration Duration entire trial : 2 year Duration recruitment : 12 month Follow-Up : 9 month Statistical Analysis : 3 month Study start : 11/2015 Anticipated study end ( final report ) : 12/2017 Duration Treatment : 48 week Statistical Methods Primary Statistical Hypothesis Sample size consideration : Emre et al NEJM 2004 find 2.1±8.2 point improvement ADAS-cog rivastigmine treatment compare worsen 0.7±7.5 point placebo 24 week ( baseline 23.8±10.2 point ) . There currently data estimate treatment effect size variability NBM DBS . Clearly small mean difference combination comparatively large standard deviation show rivastigmine study detectable appropriate power sample size ( 2*125 = 250 ) far away sample size plan study . But hope get hint considerably large effect NBM DBS . Within purely explorative analysis test null hypothesis equal mean ADAS-cog change score visit 1 visit 2 study treatment ( STN-DBS + NBM-DBS versus STN-DBS + sham-DBS ) analysis covariance ( ANCOVA ) baseline ADAS-cog covariate . Assuming small moderate correlation baseline ADAS-cog ADAS-cog change score visit 1 visit 2 sample size 2*5 = 10 patient ensure power 84 % detect standardized mean difference 2.0 significant deviation null hypothesis equal mean change score treatment significance level 0.05 . That mean able detect large effect significant , main objective pilot study . This study exploratory provide necessary data sample size consideration possible subsequent pivotal trial . Statistical Test Method nA one-sided significance level . Sample Size Parameters nA</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>1 . Age time enrollment : 35 75 year . 2 . Diagnosis idiopathic PD probable Parkinson 's disease dementia ( PDD ) define MDS consensus guideline ( Emre et al. , 2007 ) 3 . Mild moderately severe dementia define MiniMental State Examination ( MMSE ) score 10 24 4 . Duration bilateral idiopathic PD : ≥5 year motor symptom . 5 . Severity bilateral idiopathic PD med state : modify Hoehn Yahr stage ≥2 . 6 . UPDRS subset III score ≥30 med , stim state . 7 . Levodopa must improve PD symptom ≥30 % levodopa challenge test , measure UPDRS subset III score . 8 . PDD symptom onset least 2 year first symptoms PD 9 . Be willing able comply visit study related procedure ( e.g. , use remote control , charge system complete motor diary ) mentally competent , incompetent , legally authorize representative . 10 . Able understand study requirement treatment procedure provide write informed consent studyspecific test procedure perform . If mentally incompetent , legally authorize representative provide write informed consent 1 . Any significant psychiatric problem , include acute confusional state ( delirium ) , ongoing psychosis , clinically significant depression . 2 . Any current drug alcohol abuse . 3 . Any history recurrent unprovoked seizure . 4 . Any prior movement disorder treatment involve intracranial surgery device implantation . 5 . A history neurostimulation intolerance area body . 6 . Any significant medical condition likely interfere study procedure likely confound evaluation study endpoint , include terminal illness survival &lt; 12 month . 7 . Participation another drug , device , biologics trial concurrently within precede 30 day . Any trial participation approve Principal Investigators . 8 . Pregnancy , breastfeeding , lack reliable contraception</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>deep brain stimulation</keyword>
	<keyword>subthalamic nucleus</keyword>
	<keyword>Nucleus basalis Meynert</keyword>
</DOC>